All News

The researchers emphasized that individuals must advocate for new policies that could aid regulation of harmful information being shared through social media platforms.

Belzutifan (Welireg; Merck) demonstrated superior progression-free survival compared to everolimus in advanced renal cell carcinoma.

This month's Pharmacy Times Condition Watch features obesity and type 2 diabetes.

The protein STAT3 is present in approximately 70% of tumors, with elevated levels of the protein being an indicator of poor prognoses in patients.

The proposed Vaccine Injury Compensation Modernization Act is intended to bring valuable updates to the 36-year-old legislation.

Investigators also found that the results demonstrated lower death and hospitalization rates for those with advanced heart failure treated with cell therapy.

Hospice care is only a part of palliative care services.

Douglas Warner, MD, chief medical officer at eFFECTOR, provides a comprehensive overview of zotatifin and its current status in a Phase 1/2 dose escalation and expansion study, with a focus on ER+/HER2- breast cancer.

Feldman, who previously had C. diff, urges individuals to begin having conversations to help remove the stigma of the disease and raise awareness of its prevalence.

Feldman details her experience with C. diff, how the COVID-19 pandemic slowed the timeline of care, and how her surgical history and the use of antibiotics played into the disease’s onset.

Collaboration and knowledge sharing amongst rare disease researchers can be difficult, as these researchers are often spread out throughout the world.

The update also removed the maximally tolerated qualifier for statin use and the statement that said morbidity and mortality was not yet determined.

Out of the 600 infants, 169 were born prematurely, 487 did not have underlying medical conditions, and 143 had to receive invasive mechanical ventilation.

In the pharmacy, time is the ultimate value-add.

The results found that the M2e nanoparticle injection could efficiently protect individuals from influenza A viruses.

AFPs limit access to provider-prescribed specialty medications.

The products include Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution, Icatibant Injection, Esomeprazole Magnesium Capsules, and Apremilast Tablets.

Heather McArthur, MD, clinical director of breast oncology at UT Southwestern Medical Center, discusses the toxicities associated with antibody-drug conjugates (ADCs) used in breast cancer treatment at the 2023 San Antonio Breast Cancer Symposium.

The approval carries the limitation that ritlecitinib should not be used in combination with biologic immunomodulators, cyclosporine, other Janus kinase inhibitors, or other potent immunosuppressants.

There is progress being made regarding research on immunotherapies and the mutation, which adversely affects a higher number of patients in this population.

Conducting clinical trials to investigate claims regarding supplements' safety and efficacy can support greater patient wellness.

Immune cells in lung cancer are connected to allergic conditions found in eczema and asthma.

Clinical trial results show the immunogenicity, tolerability, and safety of V116 compared to a pneumococcal 20-valent conjugate vaccine for adults who had not previously received a pneumococcal vaccine.

Bivigam was initially approved by the FDA in May 2019 for the treatment of primary humoral immunodeficiency, including a group of genetic disorders.

Both individual and structural barriers were the most common hindrances to PrEP roll-out, and the investigators emphasize that efforts to remove the obstacles as well as further research can help improve PrEP implementation.

Fractional COVID-19 dosing resulted in fewer adverse effects and costs while producing similar immune responses compared to a full dose vaccine.

In the phase 3 SURMOUNT-4 trial, investigators included individuals with at least 1 weight-related complication, including hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.

Axitinib, cabozantinib, and lenvatinib are first-line treatment options.